BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, published by Academic Press Inc Elsevier Science, stands as a leading periodical in the fields of biochemistry, biophysics, cell biology, and molecular biology. With an ISSN of 0006-291X and an E-ISSN of 1090-2104, this esteemed journal has been a pivotal platform for the dissemination of groundbreaking research since its inception in 1959, continuing to publish influential findings through at least 2024. It holds a commendable Q2 ranking in Biochemistry and Q1 status in Biophysics as of 2023, reflecting its high impact and relevance in the field, supported by its strong Scopus rankings—ranking #43 in Biophysics and maintaining a presence in the top quartiles of several related categories. Although it is not an open-access journal, it provides critical insights and essential data that cater to researchers, professionals, and students keen on advancing their understanding of complex biochemical and biophysical processes. Its significant contributions to the scientific community underscore the importance of this journal as a reference point for innovative research and collaborative discourse.

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

Biomolecules is a prestigious, peer-reviewed journal published by MDPI that has been dedicated to advancing the field of biochemical research since its launch in 2011. With an impressive impact factor positioning it in Q1 for Biochemistry and Q2 for Molecular Biology as of 2023, this journal serves as a vital platform for disseminating high-quality research findings related to biological macromolecules, including proteins, nucleic acids, and carbohydrates. Operating as an Open Access journal, it ensures that vital research is accessible to all, furthering knowledge dissemination and collaboration within the scientific community. Located in Basel, Switzerland, the journal has established a significant presence in major academic databases, holding commendable Scopus rankings in both Biochemistry and Molecular Biology. Researchers, professionals, and students will find Biomolecules an invaluable resource for cutting-edge research, reviews, and insights in the rapidly evolving domains of biochemistry and molecular biology.

Biochemistry and Cell Biology, published by Canadian Science Publishing, is a prestigious journal that has been instrumental in advancing the fields of biochemistry, molecular biology, and cell biology since its inception in 1986. With an impressive scope spanning innovative research findings to comprehensive reviews, this journal serves as a vital resource for researchers, professionals, and students alike. Currently positioned in the Q2 quartile in Biochemistry and Q3 quartiles in both Cell Biology and Molecular Biology, it reflects a robust contribution to scientific discourse, placing it among reputable publications in its field. The journal boasts notable rankings within the Scopus database, highlighting its impact and relevance, and continues to be a valuable platform for disseminating pivotal research. By providing access to a wide array of articles, the journal remains committed to fostering knowledge and collaboration in the scientific community.

The CRISPR Journal, published by MARY ANN LIEBERT, INC, is a pioneering platform dedicated to advancing the field of genetics and biotechnology through innovative research focused on CRISPR technology and its diverse applications. With an impressive Q1 ranking in both Biotechnology and Genetics for 2023, this journal is positioned among the leading publications in its field, showcasing groundbreaking studies from 2019 to 2024. While currently utilizing a subscription model, the journal's commitment to open science is reflected in its efforts to make high-quality research accessible to researchers, professionals, and students. The CRISPR Journal facilitates the dissemination of knowledge related to genomic editing technologies, fostering collaboration and advancing the understanding of gene manipulation, therapeutic techniques, and agricultural innovations. As a valuable resource for cutting-edge developments in the biochemistry and genetics landscape, this journal is essential for those seeking to stay at the forefront of CRISPR research and applications.

Human Gene Therapy, an esteemed journal published by Mary Ann Liebert, Inc., is at the forefront of the rapidly evolving fields of genetics, molecular biology, and molecular medicine. With a significant impact in its domain, it is categorized in the Q2 quartile across multiple disciplines, reflecting its commitment to disseminating high-quality, impactful research. Established in 1990, the journal has continuously provided a vital platform for scientists and practitioners to explore groundbreaking developments in gene therapy, genetic engineering, and related technologies. With a focus on peer-reviewed articles that foster advancements in therapeutic applications, Human Gene Therapy serves not only as a comprehensive resource for academia but also as an essential reference for professionals engaged in genetic research and clinical practice. Although currently not open access, the journal remains a crucial source of knowledge, driving innovation and collaboration within the gene therapy community.

Molecular Cell, published by Cell Press, is a leading journal in the fields of cell biology and molecular biology. Established in 1997, this prestigious journal boasts a significant impact within the scientific community, evidenced by its impressive 2023 Scopus rankings, placing it in the top 2% of its field (Rank #10/410 in Molecular Biology, Rank #12/285 in Cell Biology). With a focus on cutting-edge research that bridges the gap between molecular genetics and cellular function, Molecular Cell serves as an essential platform for the dissemination of vital findings and innovative methodologies. Although it follows a traditional publishing model without Open Access options, its rigorous peer-review process and high standards ensure that articles published within these pages are of the utmost quality, making it an invaluable resource for researchers, professionals, and students alike seeking to stay at the forefront of scientific discovery. The journal's address is 50 Hampshire St, Floor 5, Cambridge, MA 02139, United States, reinforcing its commitment to fostering scientific excellence and collaboration.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS is a vital academic journal published by Taylor & Francis Inc, dedicated to the intricate and evolving domains of biochemistry, genetics, and molecular medicine. With an ISSN of 1525-7770 and E-ISSN of 1532-2335, this journal aims to provide a comprehensive platform for the dissemination of research findings, reviews, and methodologies related to nucleosides, nucleotides, and nucleic acids. As a research journal thriving since its inception in 2000, it reflects a diverse spectrum of studies crucial for advancing knowledge in biochemistry (ranked Q4) and genetics (Q4), while also achieving Q3 status in medicine (miscellaneous). Despite its current standing in the quartiles and Scopus rankings indicative of an emergent trajectory, the journal retains significant relevance for those delving into interdisciplinary research that intersects these fields. Researchers, professionals, and students alike can explore a plethora of original research articles, thought-provoking reviews, and updates on pioneering advances that shape our understanding of molecular biology. With its unwavering commitment to scholarly excellence, NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS continues to be an essential resource for those aiming to contribute to and stay informed about this pivotal area of scientific inquiry.